Acetylsalicylic acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Köhnke, Thomas ^a,b   Gomolka, Beate ^a   Bilal, Süleyman ^a,b   Zhou, Xiangzhi ^c   Sun, Yanping ^c,d   Rothe, Michael ^e   Baumgart, Daniel C ^a   Weylandt, Karsten H ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e LIPIDOMIX GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYDOCOSAHEXAENOIC ACID; ACETYLSALICYLIC ACID; DEXTRAN SULFATE; DOCOSAHEXAENOIC ACID; DRUG VEHICLE; LIPOXIN A; UNCLASSIFIED DRUG; 17-HYDROXY-4,7,10,13,15,19-DOCOSAHEXAENOIC ACID; ANTIINFLAMMATORY AGENT; LIPID; 17 HYDROXY 4,7,10,13,15,19 DOCOSAHEXAENOIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOPSY; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; IMAGING SOFTWARE; IN VITRO STUDY; LIPID ANALYSIS; LIQUID CHROMATOGRAPHY; MACROPHAGE; MEDIATOR; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHAGOCYTOSIS; PHENOTYPE; TANDEM MASS SPECTROMETRY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; PATHOLOGY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASPIRIN; COLITIS; DEXTRAN SULFATE; DOCOSAHEXAENOIC ACIDS; FEMALE; LIPIDS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; PHAGOCYTOSIS;

EID: 84884851903     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/748160     Document Type: Article

References (56)

1. Baumgart D. C., Carding S. R., Inflammatory bowel disease: cause and immunobiology. The Lancet 2007 369 9573 1627 1640 2-s2.0-34248136828 10.1016/S0140-6736(07)60750-8 (Pubitemid 46722636)
2. Baumgart D. C., Sandborn W. J., Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet 2007 369 9573 1641 1657 2-s2.0-34248136340 10.1016/S0140-6736(07)60751-X (Pubitemid 46722637)
3. Podolsky D. K., Inflammatory bowel disease. The New England Journal of Medicine 2002 347 6 417 429 2-s2.0-0037043658 10.1056/NEJMra020831 (Pubitemid 34851835)
4. Xavier R. J., Podolsky D. K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007 448 7152 427 434 2-s2.0-34547176642 10.1038/nature06005 (Pubitemid 47123518)
5. Takeuchi K., Smale S., Premchand P., Maiden L., Sherwood R., Thjodleifsson B., Bjornsson E., Bjarnason I., Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clinical Gastroenterology and Hepatology 2006 4 2 196 202 2-s2.0-32044465242 10.1016/S1542-3565(05)00980-8 (Pubitemid 43199690)
6. Bloomfeld R. S., Are COX-2 inhibiotrs safe for anyone. Inflammatory Bowel Diseases 2006 12 9 922 923 2-s2.0-33748461582 10.1002/ibd.3780120913 (Pubitemid 44352721)
7. El Miedany Y., Youssef S., Ahmed I., El Gaafary M., The gastrointestinal safety and effect on disease activity of etoricoxib, a selective Cox-2 inhibitor in inflammatory bowel diseases. The American Journal of Gastroenterology 2006 101 2 311 317 2-s2.0-33644900228 10.1111/j.1572-0241.2006.00384.x (Pubitemid 43381673)
8. Matuk R., Crawford J., Abreu M. T., Targan S. R., Vasiliauskas E. A., Papadakis K. A., The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2004 10 4 352 356 2-s2.0-3543086892 10.1097/00054725-200407000-00005 (Pubitemid 39029177)
9. Feagins L. A., Cryer B. L., Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Digestive Diseases and Sciences 2010 55 2 226 232 2-s2.0-76849096442 10.1007/s10620-009-1042-7
10. Okayama M., Hayashi S., Aoi Y., Nishio H., Kato S., Takeuchi K., Aggravation by selective COX-1 and COX-2 inhibitors of dextran sulfate sodium (DSS)-induced colon lesions in rats. Digestive Diseases and Sciences 2007 52 9 2095 2103 2-s2.0-34547843601 10.1007/s10620-006-9597-z (Pubitemid 47246503)
11. Tsubouchi R., Hayashi S., Aoi Y., Nishio H., Terashima S., Kato S., Takeuchi K., Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats. Digestion 2007 74 2 91 100 2-s2.0-33846687337 10.1159/000097657 (Pubitemid 46192733)
12. Morteau O., Morham S. G., Sellon R., Dieleman L. A., Langenbach R., Smithies O., Sartor R. B., Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. Journal of Clinical Investigation 2000 105 4 469 478 2-s2.0-0033997088 (Pubitemid 30127247)
13. Wallace J. L., Keenan C. M., Gale D., Shoupe T. S., Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 1992 102 1 18 27 2-s2.0-0026556835
14. Martín A. R., Villegas I., Alarcón de la Lastra C., The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. Inflammation Research 2005 54 4 145 151 2-s2.0-23844449031 10.1007/s00011-004-1337-2 (Pubitemid 41175265)
15. Kankuri E., Vaali K., Korpela R., Paakkari I., Vapaatalo H., Moilanen E., Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation 2001 25 5 301 310 2-s2.0-0035527572 10.1023/A:1012860509440 (Pubitemid 34093586)
16. Weylandt K. H., Kang J. X., Wiedenmann B., Baumgart D. C., Lipoxins and resolvins in inflammatory bowel disease. Inflammatory Bowel Diseases 2007 13 6 797 799 2-s2.0-34250373637 10.1002/ibd.20109 (Pubitemid 46909995)
17. Serhan C. N., Hamberg M., Samuelsson B., Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proceedings of the National Academy of Sciences of the United States of America 1984 81 17 I 5335 5339 2-s2.0-1542591247 (Pubitemid 14048742)
18. Parkinson J. F., Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflammation and Allergy 2006 5 2 91 106 2-s2.0-33744480779 10.2174/187152806776383125 (Pubitemid 43796671)
19. Gewirtz A. T., Collier-Hyams L. S., Young A. N., Kucharzik T., Guilford W. J., Parkinson J. F., Williams I. R., Neish A. S., Madara J. L., Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. Journal of Immunology 2002 168 10 5260 5267 2-s2.0-0037092591 (Pubitemid 34495994)
20. Fiorucci S., Wallace J. L., Mencarelli A., Distrutti E., Rizzo G., Farneti S., Morelli A., Tseng J.-L., Suramanyam B., Guilford W. J., Parkinson J. F., A β -oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proceedings of the National Academy of Sciences of the United States of America 2004 101 44 15736 15741 2-s2.0-8144222790 10.1073/pnas.0404722101 (Pubitemid 39473557)
21. Hudert C. A., Weylandt K. H., Lu Y., Wang J., Hong S., Dignass A., Serhan C. N., Kang J. X., Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proceedings of the National Academy of Sciences of the United States of America 2006 103 30 11276 11281 2-s2.0-33746625086 10.1073/pnas.0601280103 (Pubitemid 44156509)
22. Arita M., Yoshida M., Hong S., Tjonahen E., Glickman J. N., Petasis N. A., Blumberg R. S., Serhan C. N., Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proceedings of the National Academy of Sciences of the United States of America 2005 102 21 7671 7676 2-s2.0-19644369581 10.1073/pnas.0409271102 (Pubitemid 40741029)
23. Bento A. F., Claudino R. F., Dutra R. C., Marcon R., Calixto J. B., Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice. Journal of Immunology 2011 187 4 1957 1969 2-s2.0-80051922251 10.4049/jimmunol.1101305
24. Ishida T., Yoshida M., Arita M., Nishitani Y., Nishiumi S., Masuda A., Mizuno S., Takagawa T., Morita Y., Kutsumi H., Inokuchi H., Serhan C. N., Blumberg R. S., Azuma T., Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflammatory Bowel Diseases 2010 16 1 87 95 2-s2.0-74049148461 10.1002/ibd.21029
25. Melgar S., Karlsson L., Rehnström E., Karlsson A., Utkovic H., Jansson L., Michaëlsson E., Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. International Immunopharmacology 2008 8 6 836 844 2-s2.0-43049135132 10.1016/j.intimp.2008.01.036
26. Wirtz S., Neufert C., Weigmann B., Neurath M. F., Chemically induced mouse models of intestinal inflammation. Nature Protocols 2007 2 3 541 546 2-s2.0-34347262689 10.1038/nprot.2007.41 (Pubitemid 47040018)
27. Fredin M. F., Hultin L., Hyberg G., Rehnström E., Hörnquist E. H., Melgar S., Jansson L., Predicting and monitoring colitis development in mice by micro-computed tomography. Inflammatory Bowel Diseases 2008 14 4 491 499 2-s2.0-42449128334 10.1002/ibd.20343 (Pubitemid 351571828)
28. Larsson A. E., Melgar S., Rehnstrom E., Michaelsson E., Svensson L., Hockings P., Olsson L. E., Magnetic resonance imaging of experimental mouse colitis and association with inflammatory activity. Inflammatory Bowel Diseases 2006 12 6 478 485
29. Melgar S., Gillberg P. G., Hockings P. D., Olsson L. E., High-throughput magnetic resonance imaging in murine colonic inflammation. Biochemical and Biophysical Research Communications 2007 355 4 1102 1107 (Pubitemid 46366941)
30. Dieleman L. A., Palmen M. J., Akol H., Bloemena E., Peña A. S., Meuwissen S. G. M., Van Rees E. P., Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clinical and Experimental Immunology 1998 114 3 385 391 2-s2.0-0031736096 10.1046/j.1365-2249.1998.00728.x (Pubitemid 28539597)
31. Gomolka B., Siegert E., Blossey K., Schunck W.-H., Rothe M., Weylandt K. H., Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. Prostaglandins and other Lipid Mediators 2011 94 3-4 81 87 2-s2.0-79954422010 10.1016/j.prostaglandins.2010.12. 006
32. Spite M., Serhan C. N., Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circulation Research 2010 107 10 1170 1184 2-s2.0-78549283981 10.1161/CIRCRESAHA.110.223883
33. Li J., Scherl A., Medina F., Frank P. G., Kitsis R. N., Tanowitz H. B., Sotgia F., Lisanti M. P., Impaired phagocytosis in caveolin-1 deficient macrophages. Cell Cycle 2005 4 11 1599 1607 2-s2.0-39049187423
34. Wan C. P., Park C. S., Lau B. H. S., A rapid and simple microfluorometric phagocytosis assay. Journal of Immunological Methods 1993 162 1 1 7 2-s2.0-0027318744 10.1016/0022-1759(93)90400-2
35. Munkholm P., Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, Supplement 2003 18 supplement 2 1 5 2-s2.0-0141651527 (Pubitemid 37174709)
36. Lutgens M. W., Oldenburg B., Siersema P. D., Van Bodegraven A. A., Dijkstra G., Hommes D. W., De Jong D. J., Stokkers P. C. F., Van Der Woude C. J., Vleggaar F. P., Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. British Journal of Cancer 2009 101 10 1671 1675 2-s2.0-70449518319 10.1038/sj.bjc.6605359
37. Chan A. T., Giovannucci E. L., Meyerhardt J. A., Schernhammer E. S., Curhan G. C., Fuchs C. S., Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. Journal of the American Medical Association 2005 294 8 914 923 2-s2.0-23944436934 10.1001/jama.294.8.914 (Pubitemid 41215460)
38. Rosenberg L., Louik C., Shapiro S., Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer 1998 82 12 2326 2333 (Pubitemid 28283438)
39. Flossmann E., Rothwell P. M., Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. The Lancet 2007 369 9573 1603 1613 2-s2.0-34248157118 10.1016/S0140-6736(07)60747-8 (Pubitemid 46710123)
40. Rothwell P. M., Wilson M., Elwin C.-E., Norrving B., Algra A., Warlow C. P., Meade T. W., Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet 2010 376 9754 1741 1750 2-s2.0-78650215449 10.1016/S0140-6736(10)61543-7
41. Velayos F. S., Loftus E. V. Jr., Jess T., Harmsen W. S., Bida J., Zinsmeister A. R., Tremaine W. J., Sandborn W. J., Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006 130 7 1941 1949 2-s2.0-33744551277 10.1053/j.gastro.2006.03.028 (Pubitemid 43816957)
42. Stark L. A., Reid K., Sansom O. J., Din F. V., Guichard S., Mayer I., Jodrell D. I., Clarke A. R., Dunlop M. G., Aspirin activates the NF- B signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis 2007 28 5 968 976 2-s2.0-34447099200 10.1093/carcin/bgl220 (Pubitemid 47072180)
43. Zhang X., Wang Z., Zhang Y., Jia Q., Wu L., Zhang W., Impact of acetylsalicylic acid on tumor angiogenesis and lymphangiogenesis through inhibition of VEGF signaling in a murine sarcoma model. Oncology Reports 2013 29 5 1907 1913 10.3892/or.2013.2339
44. Mcilhatton M. A., Tyler J., Kerepesi L. A., Bocker-Edmonston T., Kucherlapati M. H., Edelmann W., Kucherlapati R., Kopelovich L., Fishel R., Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model. Cancer Prevention Research 2011 4 5 684 693 2-s2.0-79955837946 10.1158/1940-6207.CAPR-10-0319
45. Mahmoud N. N., Dannenberg A. J., Mestre J., Bilinski R. T., Churchill M. R., Martucci C., Newmark H., Bertagnolli M. M., Townsend C.M. J., Beauchamp R. D., Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998 124 2 225 231 2-s2.0-0031856415 10.1016/S0039-6060(98)70124-2 (Pubitemid 28372920)
46. Tian Y., Ye Y., Gao W., Chen H., Song T., Wang D., Mao X., Ren C., Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. International Journal of Colorectal Disease 2011 26 1 13 22
47. Newmark H. L., Nutrient density: an important and useful tool for laboratory animal studies. Carcinogenesis 1987 8 7 871 873 2-s2.0-0023258778 (Pubitemid 17133573)
48. González-Périz A., Planagumà A., Gronert K., Miquel R., López-Parra M., Titos E., Horrillo R., Ferré N., Deulofeu R., Arroyo V., Rodés J., Clària J., Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. The FASEB Journal 2006 20 14 2537 2539 2-s2.0-33947505559 10.1096/fj.06-6250fje (Pubitemid 44953772)
49. Spite M., Norling L. V., Summers L., Yang R., Cooper D., Petasis N. A., Flower R. J., Perretti M., Serhan C. N., Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009 461 7268 1287 1291 2-s2.0-70350678971 10.1038/nature08541
50. Spite M., Summers L., Porter T. F., Srivastava S., Bhatnagar A., Serhan C. N., Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress. British Journal of Pharmacology 2009 158 4 1062 1073 2-s2.0-70149123025 10.1111/j.1476-5381.2009.00234.x
51. Sun Y.-P., Oh S. F., Uddin J., Yang R., Gotlinger K., Campbell E., Colgan S. P., Petasis N. A., Serhan C. N., Resolvin D1 and its aspirin-triggered 17R epimer: stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. Journal of Biological Chemistry 2007 282 13 9323 9334 2-s2.0-34248233132 10.1074/jbc.M609212200 (Pubitemid 47104612)
52. Lima-Garcia J. F., Dutra R. C., Da Silva K. A. B. S., Motta E. M., Campos M. M., Calixto J. B., The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. British Journal of Pharmacology 2011 164 2 278 293 2-s2.0-80051953486 10.1111/j.1476-5381.2011.01345.x
53. Weylandt K. H., Krause L. F., Gomolka B., Chiu C.-Y., Bilal S., Nadolny A., Waechter S. F., Fischer A., Rothe M., Kang J. X., Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF- α Carcinogenesis 2011 32 6 897 903 2-s2.0-79958204979 10.1093/carcin/bgr049
54. Godson C., Mitchell S., Harvey K., Petasis N. A., Hogg N., Brady H. R., Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. Journal of Immunology 2000 164 4 1663 1667 2-s2.0-0034651737 (Pubitemid 30108713)
55. Prescott D., McKay D. M., Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. International Journal of Colorectal Disease 2011 2301 3 G487 G497 10.1152/ajpgi.00042.2011
56. Krishnamoorthy S., Recchiuti A., Chiang N., Yacoubian S., Lee C.-H., Yang R., Petasis N. A., Serhan C. N., Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proceedings of the National Academy of Sciences of the United States of America 2010 107 4 1660 1665 2-s2.0-76549124239 10.1073/pnas.0907342107